

**Serum Levels of AFP after Interferon-Based Therapy with
Ribavirin for Genotype 4 Chronic HCV Patients**

*Thesis Submitted in Fulfillment for the Master Degree in
Tropical Medicine*

By

Shaimaa Mohamed Abdou Dauoud

M.B.B.Ch

Supervisors

Gamal Esmat, MD

Professor of Tropical Medicine

Faculty of Medicine –Cairo University

Olfat Shaker, MD

Professor of Medical Biochemistry

Faculty of Medicine- Cairo University

Maissa El Raziky , MD

Professor of Tropical Medicine

Faculty of Medicine- Cairo University

Faculty of Medicine

Cairo University

2009

بسم الله الرحمن الرحيم

(و قل اعملوا فسيرى الله عملكم و رسوله و المؤمنون و ستردون إلى عالم الغيب و
الشهادة فينبئكم بما كنتم تعملون) صدق الله العظيم

سورة التوبة – اية ١٠٥

*I have to thank **ALLAH** a lot for the strength He-His *AlMighty*- gave to me to achieve this work and I'm praying to let it for the benefit of all people.*

*I am greatly honored to express my deep gratitude and faithfulness to **Dr. Gamal Esmat**, Professor of Tropical Medicine, Cairo University for his sincere guidance, his help and support throughout the work. His fatherhood attitude encouraged me a lot throughout this work and even before it.*

*My deep thanks and appreciation to **Dr. Maissa EL-Raziky**, Professor of Tropical Medicine, Cairo University, for her time and effort in revision of this work. Her sincere pieces of advice to me were really so precious and beneficial not only in this work but also in many aspects of scientific research in general. She was very considerate and helpful indeed.*

*I would like to thank **Dr. Olfat Shaker**, Professor of Medical Biochemistry, Cairo University, for her kindness, sincere encouragement and patience with me.*

*Very special thanks to **Dr. Wafaa El-Akel**, who helped me a lot and clarified to me many facts that were really useful in the scientific research.*

*Also I have to thank **Schistosomal Liver Unit-Cairo University** for providing me with the kits needed in this study.*

*Many thanks to all **my family members** who gave me all care and support to fulfill this work.*

My deep thanks to all my colleagues and all patients included in this work.

Shaimaa Mohamed Abdou

List of Contents

Acknowledgement	ii
List of Abbreviations	v
List of Figures	viii
List of Tables	x
Abstract	xiii
Introduction	١
Aim of Work	٣
Review of literature	
• Chapter I :Alpha feto-protein	٤
• Chapter II :Treatment of chronic hepatitis C infection	20
Participants and methods	72
Results	77
Discussion	117
Summary	123
Conclusions	125
Recommendations	126
References	127
الملخص العربي	

List of Abbreviations

- **AASLD:** American Association for the Study of Liver Diseases
- **AFP:** Alpha fetoprotein
- **AFP-L** : Alpha fetoprotein-lectin
- **ALT:** Alanine aminotransferase
- **AST :** Aspartate Aminotransferase
- **ANA:** Anti-Nuclear Antibody
- **ATP:** Adenosine Triphosphate
- **BMI:** Body Mass Index
- **bp:** base pair
- **CBC :** Complete Blood Picture
- **CD4+:** T-helper cell
- **CD8+:** Cytotoxic T cell
- **CLD:** Chronic Liver Disease
- **CHC :** Chronic Hepatitis C
- **CIFN:** Consensus Interferon
- **CTP :** Child-Turcotte-Pugh
- **DDB:**Dimethyl-4, 4'-dimethoxy-5,6,5',6'dimethylene dioxymethylene-2, 2'-dicarboxylate
- **DDW :** Digestive Diseases Week
- **dsRNA:** double-stranded RNA
- **EIA:** Enzyme Immunometric Assay
- **EVR:** Early Virological Response
- **ETR :**End of Treatment Response
- **FDA:** Food and Drug Administration
- **GFR :** Glomerular Filtration Rate
- **GGT:** Gamma glutamyl transaminase
- **GTP:** Gamma transpeptidase
- **HAART :** Highly Active Antiretroviral Therapy
- **HAI:** Histological Activity Index
- **Hb:** Hemoglobin

- **HBcAb:** Hepatitis B core antibody
- **HBsAg:** Hepatitis B surface antigen
- **HCC:** Hepatocellular carcinoma
- **HCV:** Hepatitis C virus
- **HDC:** Histamine dihydrochloride
- **HIV:** Human Immunodeficiency Virus
- **HP:** Hepatocyte Proliferation
- **HRP :** Horseradish peroxidase
- **HS:** Highly Significant
- **IFN:** Interferon
- **IL:** Interleukin
- **IU:** International Unit
- **IV:** Intravenous
- **IMPDH:** Inosine 5'-monophosphate dehydrogenase
- **IMU:** International Million Unit
- **INR:** International Normalized Ratio
- **IRES:** Internal Ribosome Entry Site
- **LCA:** Lectin Lens Culinaris Agglutinin
- **LhRNAs :** long hairpin RNAs
- **LPS:** Lipopolysaccharide
- **MiRNA :** micro-RNA
- **MMP:** Matrix Metalloproteases
- **MMPD :** Merimepodib
- **mPEG:** Monomethoxy polyethylene glycol
- **mRNA:** Messenger RNA
- **NF Kappa B:** nuclear factor-Kappa B
- **NIH:** National Institute of Health
- **NK:** Natural Killer Cell
- **NS:** Non Structural
- **NSGCT:** Non-Seminomatous Germ Cell Tumours
- **NS5B:** Non structural 5 B
- **5'NTR :** 5' non translated region

- **PAT:** Parental anti-schistosomal treatment
- **PCR:** Polymerase Chain Reaction
- **PEG-IFN :** Pegylated Interferon
- **PIs :** Protease Inhibitors
- **PO:** Per-oris.
- **PPV:** Positive Predictive Value
- **PT :** Prothrombin Time
- **RBCs:** Red Blood Cells
- **RIA:** Radioimmunoassay
- **RNA:** Ribonucleic acid
- **RNAi:** RNA interference
- **RTPCR:** Reverse-Transcription Polymerase Chain Reaction
- **RVR :** Rapid Virologic Response
- **SC :** Subcutaneously
- **SD :** Standard Deviation
- **SI :** Silymarin
- **siRNAs:** Small interfering RNAs
- **SOD:** Superoxide dismutase
- **STAT :** Specifically Targeted Antiviral Therapy
- **STAT –C :** Specifically Targeted Antiviral Therapy for Hepatitis C
- **SVR:** Sustained Virologic Response
- **Th1:** T – helper 1
- **Th2:** T – helper 2
- **TNF:** Tumour Necrosis Factor
- **TLR:** Toll-Like Receptor
- **Tα -1:** Thymosin alpha 1
- **ULN:** Upper limit of normal
- **WBC:** White Blood Cells

List of Figures

Figure I	Molecular configurations of human AFP, human albumin, and human Gc DBP protein	5
Figure II	Model structure and genome organization of hepatitis C virus	57
Figure 1	Sex distribution among SVR and non-SVR studied patients	78
Figure 2	Pre-treatment inflammatory activity of the studied patients	82
Figure 3	The relation between HAI difference and the study outcome	83
Figure 4	Pre-treatment fibrosis stage of the studied patients	84
Figure 5	Mean levels of AFP before and after treatment in relation to treatment outcome	87
Figure 6	Box plot showing AFP values before and after treatment in relation to response to treatment	87
Figure 7	Scatter plot showing pre-treatment AFP level versus age of the patients	89
Figure 8	Scatter plot showing pre-treatment AFP level versus AST of the studied patients	91
Figure 9	Scatter plot showing pre-treatment AFP level versus platelet count of the studied patients	92
Figure 10	Scatter plot showing pre-treatment AFP level versus baseline inflammation of the studied patients	94
Figure 11	Scatter plot showing pre-treatment AFP level versus baseline fibrosis in the patients	95
Figure 12	Scatter plot showing AFP difference versus BMI of the patients at 48 weeks	98

Figure 13	Scatter plot showing the relation between AFP difference and fibrosis change percent	101
Figure 14	The relation between pre-treatment AFP and inflammatory activity in the studied patients	104
Figure 15	The relation between AFP difference and inflammatory activity in studied patients	104
Figure 16	Pre-treatment AFP in relation to fibrosis stages in studied patients	107
Figure 17	AFP difference in relation to fibrosis stages in studied patients	107
Figure 18	Pre-treatment AFP levels versus steatosis difference in the studied patients	110
Figure 19	AFP difference versus steatosis difference in the studied patients	110
Figure 20	Pre-treatment AFP levels versus fibrosis difference in the studied patients	114
Figure 21	AFP difference versus fibrosis difference in the studied patients	114

List of Tables

Table I	Classification of Recommendations of AASLD, 2009 for Treatment of HCV	31
Table II	Treatment According to Stages of Chronic Kidney Diseases (KDIGO)2008	47
Table 1a	Sex distribution of the studied patients	78
Table 1b	Sex distribution among SVR and non-SVR studied patients	78
Table 1c	Age ,baseline BMI and BMI difference of the studied patients	78
Table 2	Risk factors for hepatitis in the studied patients	79
Table 3	Pre-treatment biochemical and virological profile of the studied patients	80
Table 4	Pre-treatment complete blood picture of the studied patients	80
Table 5	Alpha fetoprotein (AFP) pre-treatment levels in the studied patients	81
Table 6	Pre-treatment inflammatory activity of the studied patients	81
Table 7	HAI, HAI difference and HAI change percent in the biopsy of the studied patients	82
Table 8	Pre-treatment fibrosis stage of the studied patients	84
Table 9	Pre-treatment steatosis in the biopsy of the studied patients	84

Table 10	Steatosis change percent in the biopsy of the studied patients	85
Table 11	Comparison of AFP pretreatment, post treatment and AFP difference in relation to response to treatment	86
Table 12	Correlation between pre-treatment AFP log values, age and baseline BMI of the studied patients	88
Table 13	Correlation between pre-treatment AFP log values and liver biochemical profile of the studied patients	90
Table 14	Correlation between pre-treatment AFP log values and complete blood picture of the studied patients	92
Table 15	Correlation between AFP log values and serum glucose levels, serum creatinine levels and viral load of the studied patients	93
Table 16	Correlation between pre-treatment AFP log values and baseline biopsy results of the studied patients	94
Table 17	Changes in liver biopsies of the studied patients	96
Table 18	Correlation between pre-treatment AFP log values and AFP difference of the studied patients	96
Table 19	Pre-treatment AFP univariate and multivariate analyses	97
Table 20	Correlation between AFP difference log values and age of the studied patients	97
Table 21	Correlation between AFP difference log values and BMI difference at 24, 48,72 after starting treatment in the studied patients	98
Table 22	Correlation between AFP difference log values and pre-treatment ALT, AST or AFP folds of the studied patients	99

Table 23	Correlation between AFP difference log values and liver biopsy results difference of the studied patients	100
Table 24	Comparison of AFP pre treatment and AFP difference in relation to inflammatory activity before treatment	103
Table 25	Comparison of AFP pre treatment and AFP difference in relation to fibrosis stages before treatment	106
Table 26	Comparison of AFP pre treatment and AFP difference level in relation to steatosis changes	109
Table 27	Comparison of AFP pre treatment and AFP difference level in relation to inflammatory activity changes	112
Table 28	Comparison of AFP pre treatment and AFP difference level in relation to fibrosis changes	113
Table 29	AFP difference univariate and multivariate analyses	115

Abstract

Key words:

AFP: Alpha feto-protein, HCC: Hepatocellular carcinoma,

HCV: Hepatitis C virus, PEG-IFN: pegylated interferon,

SVR: sustained virological response.

Aim: Compare changes in AFP levels before and after interferon treatment in responders and non-responders with liver histopathological changes and to verify the possibility of using AFP as a predictor of response to interferon-ribavirin therapy in chronic HCV genotype 4 patients.

Background and methods: HCV infection is a major health problem in Egypt and it is a major cause of chronic hepatitis and hepatic fibrosis that progresses in some patients to HCC. AFP has been widely used as a diagnostic marker for HCC. Elevated levels of AFP can be seen in chronic HCV.

This prospective study recruited 79 chronic HCV patients (genotype 4) who received treatment in the form of PEG-IFN alfa-2b 100 µg weekly and ribavirin 11mg/kg/day for 48 weeks then followed up by AFP level and liver biopsy.

Results: AFP level decreased in all patients with better results in SVR patients. Histopathological improvements occurred in most patients after treatment. Pre-treatment AFP was correlated with age, fibrosis, inflammation, transaminases, hemoglobin, platelet count and AFP difference.

Conclusions: AFP can be used as a good predictor for treatment response before starting treatment in chronic HCV genotype 4 patients.

Introduction

Chronic hepatitis C virus (HCV) infects approximately 170 million people world wide. It is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma and represents the most frequent cause for liver transplantation in the US and Europe (**Lauer, 2001**).

Genotypes 1, 2 and 3 of the Hepatitis C virus (HCV) are widely distributed throughout Western countries and the Far East (Japan, China, Taiwan, and Thailand). Types 5 and 6 are mainly confined to South Africa and Southeast Asia, respectively, in contrast to type 4, which is predominant in the Middle East and Central Africa (**Maertens, 1997**).

Hepatitis C virus (HCV) infection is a major health problem in Egypt, where the seroprevalence is 10-20-fold higher than that in the United States (**Ray, 2000**). Egypt reports the highest prevalence of HCV worldwide, ranging from 6% to more than 40% among regions and demographic groups (**Lehman, 2009**).

Pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy given for 48 weeks is established as the standard therapy for patients with chronic HCV infection with genotypes 1 and 4 (**NIH Consensus, 2002**). This treatment has yielded overall sustained virological response (SVR) rates of 54% to 69% in randomized controlled phase III clinical trials (**Zeuzem, 2005**). However, response to treatment is not uniform across all populations (**Dienstag, 2006b**) and is dependent on various viral and host factors.

Alpha-fetoprotein (AFP) is α 1-globulin secreted by fetal hepatocytes and in a small amount by other cells of the fetal gastrointestinal tract. Physiologically, in human adults an increased AFP level is present in the serum of pregnant women (**Cedrone et al., 2000 and Chu et al., 2001**).

AFP has been widely used as a diagnostic marker for hepatocellular carcinoma (HCC). However, there are some patients showing continuous high AFP values but no evidence of HCC, and some studies have defined such patients as a high risk group for HCC (**Murashima et al., 2006**).

In vitro study has shown that interferon (IFN) inhibits cell proliferation and enhances apoptosis as well as specific cytotoxic T-lymphocytes against HCC, resulting in direct anticancer actions. Since AFP is a significant predictor for HCC, therapeutic strategies for hepatitis C, e.g. long-term low-dose IFN treatment, may reduce hepatocarcinogenesis (**Murashima et al., 2006**).

Hepatic progenitor cells (HPC) arise in the periportal region of the liver and may be responsible for liver regeneration. They express high levels of AFP, certain keratin markers, and GGT (**Dabeva, 1993**). Their presence is related to the severity of fibrosis (**Tsamandas et al., 2006**) and their activation has been documented in parallel with cells associated with the development of fibrosis (stellate cells) (**Yin et al., 2002**). Quite interestingly, HPC expression has recently been associated with response to treatment, being higher in non-responders and relapsers compared with responders (**Tsamandas et al., 2006**).

Predictors of response to therapy serve as decision tools for physicians to help identify patients who are likely or unlikely to achieve an SVR, and to consider pre-treatment counseling in those patients with a reduced likelihood of successful therapy, perhaps sparing them the side effects and cost of therapy. Therefore, knowledge of predictors to these therapies is extremely valuable (**Abdo, 2009**).